XM does not provide services to residents of the United States of America.
W
W

Walgreens

Technical Summary

IndicatorValueTrend
IndicatorValueTrend
IndicatorValueTrend
IndicatorS3S2S1PR1R2R3

News

UK retail warns of inflation, job losses from budget, seeks Reeves meeting

UPDATE 1-UK retail warns of inflation, job losses from budget, seeks Reeves meeting Over 80 retail bosses sign letter to finance minister Say retail faces 7 bln stg in extra annual costs from 2025 Wants to work with government to find solution Adds latest number of signatories paragraph 2, comment from spokesperson for Prime Minister Keir Starmer 7 and 8 By James Davey LONDON, Nov 19 (Reuters) - Britain's biggest retailers have written to finance minister Rachel Reeves to warn her that last mont
A
G
K
M
N
T
W

S&P 500 top and bottom performing stocks at about 02:30 p.m. EST

BUZZ - S&P 500 top and bottom performing stocks at about 02:30 p.m. EST S&P 500 .SPX Top Performers Percent Change Super Micro Computer Inc SMCI.OQ +22.8% Henry Schein Inc HSIC.OQ +5.9% CVS Health Corp CVS.N +5.5% Walgreens Boots Alliance Inc WBA.OQ +5.4% Moderna Inc MRNA.OQ +5.2% Bottom Performers Percent Change Amentum Holdings Inc AMTM.N -9.0% P
W
U
U

S&P 500 top and bottom performing stocks at about 12:00 p.m. EST

BUZZ - S&P 500 top and bottom performing stocks at about 12:00 p.m. EST S&P 500 .SPX Top Performers Percent Change Super Micro Computer Inc SMCI.OQ +16.7% Tesla Inc TSLA.OQ +6.9% Walgreens Boots Alliance Inc WBA.OQ +6.4% Vistra Corp VST.N +6.1% Moderna Inc MRNA.OQ +5.9% Bottom Performers Percent Change Amentum Holdings Inc AMTM.N -7.8% Uber Technol
T
W
U
U
U

About 100 decongestant lawsuits claiming bogus ingredient tossed

About 100 decongestant lawsuits claiming bogus ingredient tossed By Diana Novak Jones Nov 13 (Reuters) - A New York federal judge on Tuesday dismissed about 100 lawsuits that claimed Procter & Gamble PG.N , Haleon HLN.L and other companies knowingly marketed and sold over-the-counter medications containing a decongestant that didn’t work. U.S. District Judge Brian Cogan in Brooklyn dismissed the lawsuits against medication manufacturers and grocery chains filed by consumers after a unanimous U
B
W

Baltimore wins $266 million in opioid case against distributors

Baltimore wins $266 million in opioid case against distributors By Brendan Pierson Nov 13 (Reuters) - The city of Baltimore won $266 million in its lawsuit accusing top drug distributors McKesson MCK.N and Cencora COR.N of fueling an epidemic of opioid addiction in the U.S., and is expected to seek billions more in the next phase of the case. A six-person jury in the Circuit Court for Baltimore found McKesson responsible for $192 million and Cencora for $74 million on Tuesday following a nearly
W
M

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.